IP Library Granted Patent US 9,422,244
Granted Patent B2
US 9,422,244 · App. 13/574,176 · Granted Aug 23, 2016

Synthesis of substituted pyrazoline carboxamidine derivatives

Inventors: Arnold van Loevezijn (Weesp, NL); Josephus H. M. Lange (Weesp, NL); Gerrit A. Barf (Weesp, NL); Arnold P. den Hartog (Weesp, NL)
Assignee: Abbvie Bahamas Ltd.
C07D231/06C07D231/54C07D409/04C07D409/12C07D491/107C07D513/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,422,244
App. No.
13/574,176
Granted
Aug 23, 2016
Kind
B2
Abstract

This invention relates to organic chemistry, in particular to processes for the preparation of pyrazoline carboxamidine derivatives of formula (I), known as potent 5-HT6 antagonists. The invention also relates to novel intermediates of these compounds. wherein the symbols have the meanings given in the description.

Claims (24)

1. A process for the preparation of a compound of formula (I):

or a tautomer, stereoisomer, or a pharmacologically acceptable salt thereof, wherein:

R 7 represents a monocyclic, or a fused-bicyclic aromatic or hetero-aromatic group, which groups are unsubstituted or substituted with one to five substituents which can be the same or different, selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, cyano, C 1-3 -alkyl, C 1-3 -alkoxy, hydroxy, amino, acetyl, acetamido, trifluoroacetamido, —CONH 2 , —SO 2 NH 2 and —CO 2 H or R 7 represents a 2-aryl-ethenyl group or a 2-aryl-ethynyl group, or

R 7 represents a piperidinyl group unsubstituted or substituted with one to four fluoro atoms or a CF 3 group, or

R 7 represents a 2,3-dihydroindolyl group or a benzimidazol-2-one group

comprising the steps of:

(i) reacting 2,3-diaza-spiro[4.4]non-2-ene or 2,3-diaza-spiro[4.4]non-1-ene, or salts thereof with ethyl isothiocyanate, to yield 2,3-diazaspiro[4.4]non-3-ene-2-carbothioic acid ethylamide or its tautomer;

(ii) reacting the latter with iodomethane or methyl p-toluenesulfonate yielding N-ethyl-2,3-diaza-spiro[4.4]non-3-ene-2-carboximido-thioic acid methyl ester,

(iii) reacting the obtained N-ethyl-2,3-diaza-spiro[4.4]non-3-ene-2-carboximido-thioic acid methyl ester with a sulfonamide compound of formula R 7 SO 2 NH 2 , wherein R 7 has the meaning given above, to give a compound of formula (I):

(iv) isolating the compound of formula (I) from the reaction mixture.

2. A process as claimed in claim 1 , for the preparation of a compound of formula (I), wherein:

R 7 represents a monocyclic, or a fused-bicyclic aromatic or hetero-aromatic group, which groups are unsubstituted or substituted with one to five substituents which can be the same or different, selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, cyano, C 1-3 -alkyl, C 1-3 -alkoxy, hydroxy, amino, acetyl, acetamido, trifluoroacetamido, —CONH 2 , —SO 2 NH 2 and —CO 2 H or R 7 represents a 2-aryl-ethenyl group or a 2-aryl-ethynyl group, or

R 7 represents a piperidinyl group, or

R 7 represents a 2,3-dihydroindolyl group or a benzimidazol-2-one group.

3. A process as claimed in claim 1 wherein R 7 represents a monocyclic, or a fused-bicyclic aromatic or hetero-aromatic group, which groups are unsubstituted or substituted with one or two substituents chosen from methyl, methoxy, fluoro, chloro, bromo, cyano, acetamido, trifluoroacetamido, trifluoromethyl, amino or hydroxy.

4. A process as claimed in claim 1 , for the preparation of a compound of formula

and tautomers and salt forms thereof,

comprising the steps of:

(i) reacting 2,3-diaza-spiro[4.4]non-2-ene or 2,3-diaza-spiro[4.4]non-1-ene, or salts thereof, with ethyl isothiocyanate, to yield 2,3-diazaspiro[4.4]non-3-ene-2-carbothioic acid ethylamide or its tautomer

(ii) reacting the latter with iodomethane or methyl p-toluenesulfonate yielding N-ethyl-2,3-diaza-spiro[4.4]non-3-ene-2-carboximido-thioic acid methyl ester,

(iii) reacting the latter, as free base or salt thereof, with 4-acetamidobenzenesulfonamide yielding N-(4-{[(2,3-diaza-spiro[4.4]non-3-en-2-yl)-ethylamino-methylene]-sulfamoyl}-phenyl)-acetamide

(iv) deprotecting the latter under acidic conditions, yielding 4-amino-N-[(2,3-diaza-spiro[4.4]non-3-en-2-yl)-ethylamino-methylene]-benzenesulfonamide

5. A process as claimed in claim 4 , wherein step (iii) consists of reacting N-ethyl-2,3-diaza-spiro[4.4]non-3-ene-2-carboximidothioic acid methyl ester with sulfanilamide yielding 4-amino-N-[(2,3-diaza-spiro[4.4]non-3-en-2-yl)-ethylamino-methylene]-benzenesulfonamide:

6. A compound selected from those of the formulae:

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2013
From: ABBOTT HEALTHCARE PRODUCTS B.V.
To: ABBOTT HOSPITALS LIMITED
Reel/Frame 031717/0292 →
CHANGE OF NAME Recorded Dec 4, 2013
From: ABBOTT HOSPITALS LIMITED
To: ABBVIE BAHAMAS LTD.
Reel/Frame 031717/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2012
From: VAN LOEVEZIJN, ARNOLD; LANGE, JOSEPHUS H.M.; BARF, GERRIT A.; DEN HARTOG, ARNOLD P.
To: ABBOTT HEALTHCARE PRODUCTS B.V.
Reel/Frame 029156/0096 →
Priority Claims (1)
EP 10152097 · Jan 29, 2010 · regional
Continuity (2)
Provisional Application 61299363 · Jan 29, 2010
Related Publication 20130060041A1 · Mar 7, 2013